New Abbott Test Can Help Doctors Detect the Presence of Two Important Health Issues

Thu Mar 28, 2013 8:00am EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130328:nPnCG84768


ABBOTT PARK, Ill.,  March 28, 2013  /PRNewswire/ -- Abbott (NYSE: ABT) today
announced that the ARCHITECT AFP test, which may help doctors detect serious
birth defects and the progression of testicular cancer, received U.S. Food and
Drug Administration (FDA) approval. Biomarkers, such as alpha-fetoprotein (AFP),
are substances in the body that physicians can measure to identify the progress
of diseases or conditions as well as to evaluate the effectiveness of
treatments. AFP has unique traits that help doctors detect two very different
health issues: fetal birth defects and the progression of testicular cancer.  

AFP and Birth Defects1, 2Neural tube defects (NTDs) are serious fetal birth
defects of the brain and spine that occur very early in development. When the
neural tube, a structure that develops into the brain and spinal cord, fails to
close properly, AFP is thought to leak directly from the fetus into the mother's
amniotic fluid, causing unexpectedly high levels of AFP in the mother's blood. A
blood test that measures AFP can help doctors determine if a woman is carrying a
fetus affected with birth defects, such as anencephaly (the absence of a large
part of the brain and the skull) and spina bifida (the incomplete closing of the
backbone and spinal canal). Treatments for NTDs focus on closing the defect with
surgery (including surgery before birth) and treating or addressing related
symptoms such as excess fluid in the brain and bladder and bowel problems.  

AFP and Testicular Cancer3, 4, 5 Men with one type of testicular cancer, called
nonseminoma germ cell, have elevated AFP levels present in their bloodstreams.
Blood tests to measure AFP can be used to evaluate responses to treatment. By
monitoring disease progression and seeking treatment when necessary, testicular
cancer can be a highly treatable and usually curable cancer.

"The ARCHITECT AFP assay is a valuable tool that will help physicians obtain
reliable measurements of this protein for use in guiding critical patient
treatment decisions," said  Brian Blaser, executive vice president, Diagnostics
Products, Abbott. "Abbott is pleased to offer this important assay to our
customers to positively affect patient care."  

About the  ARCHITECT AFP  Assay
The new assay runs on Abbott's fully-automated ARCHITECT  i2000,  i2000SR, 
ci8200, and  ci16200 analyzers, and is available in  the United States, CE
marked, and non-regulated countries.  

Intended Use
The ARCHITECT AFP assay is a chemiluminescent microparticle immunoassay (CMIA)
for the quantitative determination of alpha-fetoprotein (AFP) in:

1Human serum or plasma to aid in monitoring disease progression during the
course of disease and treatment of patients with nonseminomatous testicular
cancer. 2Human serum, plasma, and amniotic fluid at 15 to 21 weeks gestation to
aid in the detection of fetal open neural tube defects (NTD). Test results when
used in conjunction with ultrasonography or amniography are a safe and effective
aid in the detection of fetal open NTD.

About Abbott Diagnostics
Abbott is a global leader in  in vitro  diagnostics and offers a broad range of
innovative instrument systems and tests for hospitals, reference labs, molecular
labs, blood banks, physician offices and clinics. With more than 22,000
customers in more than 100 countries, Abbott's diagnostic products offer
customers automation, convenience, bedside testing, cost effectiveness and
flexibility. Abbott has helped transform the practice of medical diagnosis from
an art to a science through the company's commitment to improving patient care
and lowering costs.

About Abbott
Abbott is a global healthcare company devoted to improving life through the
development of products and technologies that span the breadth of healthcare.
With a portfolio of leading, science-based offerings in diagnostics, medical
devices, nutritionals and branded generic pharmaceuticals, Abbott serves people
in more than 150 countries and employs approximately 70,000 people.  

Visit Abbott at  www.abbott.com  and connect with us on Twitter at @AbbottNews.

 1  Burke, B. et al. Preventing Neural Tube Birth Defects:A Prevention Model and Resource Guide. Department of Health and Human Services and the Centers for Disease Control and Prevention. April 2009.                                           
 2  Neural Tube Defects (NTDs) Overview. National Institute of Child Health and Human Development, November 2012.                                                                                                                                  
 3  Lange PH, McIntire KR, Waldmann TA, et al.Serum alpha fetoprotein and human chorionic gonadotropin in the diagnosis and management of nonseminomatous germ-cell testicular cancer.  New England  Journal of Medicine.  1976; 295(22):1237-40.  
 4  Kohn J, Orr AH, McElwain TJ, et al. Serum-alpha-fetoprotein in patients with testicular tumours.  Lancet  1976; 2: 433-6.                                                                                                                      
 5  Testicular Cancer Treatment (PDQ®): Health Professional Version. National Cancer Institute. January 2012.                                                                                                                                      


SOURCE  Abbott


Media, Darcy Ross, +1-847-937-3655, Jessica Masuga, +1-847-935-0650, Financial,
Tina Ventura, +1-847-935-9390

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.